化合物 Quisinostat 2HCl|T6865|TargetMol

Quisinostat dihydrochloride
875320-31-3

询价 1removed 起订

上海更新日期：2024-09-29

TargetMol中国（陶术生物）

VIP3年

联系人：邵小姐

手机：4008200310 拨打

邮箱：marketing@tsbiochem.com

产品详情:

中文名称：: 化合物 Quisinostat 2HCl

英文名称：: Quisinostat dihydrochloride

CAS号：: 875320-31-3

品牌：: TargetMol

产地：: 美国

保存条件：: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice.

纯度规格：: 97.13%

产品类别：: 抑制剂

货号：: T6865

Product Introduction

Bioactivity

名称	Quisinostat dihydrochloride
描述	Quisinostat dihydrochloride (JNJ26854165(Quisinostat) 2HCl) is a novel second-generation HDAC inhibitor with highest potency for HDAC1 with IC50 of 0.11 nM in a cell-free assay, modest potent to HDACs 2, 4, 10, and 11; greater than 30-fold selectivity against HDACs 3, 5, 8, and 9 and lowest potency to HDACs 6 and 7. Phase 2.
细胞实验	All cell lines are obtained from American Type Culture Collection and cultured according to instructions. The effect of HDAC inhibitors on cell proliferation is measured using an MTT. Proliferation of non–small cell lung carcinoma (NSCLC) cell lines is assessed using an Alamar Blue–based assay. For proliferation of hematologic cell lines, cells are incubated for 72 hours and the cytotoxic activity is evaluated by MTS assay. Data are presented as mean IC50 or IC40 ± SD of at least three independent experiments.(Only for Reference)
激酶实验	HDAC activity assays : In all cases, full-length HDAC proteins are expressed using baculovirus-infected Sf9 cells. In addition, HDAC3 is coexpressed as a complex with human NCOR2. For assessing activity of HDAC1-containing cellular complexes, immunoprecipitated HDAC1 complexes are incubated with an [3H]acetyl- labeled fragment of histone H4 peptide [biotin-(6-aminohexanoic)Gly-Ala-(acetyl[3H])Lys-Arg-His-Arg-Lys-Val-NH2] in a total volume of 50μL enzyme assay buffer (25 mM HEPES (pH 7.4), 1 M sucrose, 0.1 mg/mL BSA and 0.01% (v/v) Triton X-100). Incubation is performed for 45 minutes at 37 °C (immunoprecipitates) or 30 min at room temperature. Before addition of substrate, HDAC inhibitors are added at increasing concentrations and preincubated for 10 minutes at room temperature. After incubation, the reaction is quenched with 35μL stop buffer (1 M HCl and 0.4 M acetic acid). Released [3H]acetic acid is extracted with 800μL ethyl acetate and quantified by scintillation counting. Equal amounts of HDAC1 are immunoprecipitated as indicated by Western blot analysis. HDAC1 activity results are presented as mean ± SD of three independent experiments on a single lysate.
体外活性	Quisinostat 在包括所有肺、乳腺、结肠、前列腺、大脑和卵巢肿瘤细胞系在内的实体和血液恶性肿瘤细胞系中展现出广谱抗增殖活性，其IC50值介于3.1-246 nM之间，与vorinostat、R306465、panobinostat、CRA-24781或mocetinostat相比，在测试的各种人类癌症细胞系中表现出更强的功效。[1] 最近的研究显示，Quisinostat通过导致Mcl-1耗竭和Hsp72诱导在低纳摩尔浓度下促进骨髓瘤细胞死亡。[2]
体内活性	在HDAC1敏感型A2780卵巨细胞肿瘤筛选模型中，Quisinostat以其最大耐受剂量（10 mg/kg i.p. 和 40 mg/kg p.o.）连续3天给药，引发HDAC1调控的荧光反应，这预示了肿瘤生长抑制。此外，与5-氟尿嘧啶/亚叶酸钙相比，Quisinostat在抑制C170HM2结直肠肝转移癌的生长上显示出更强的抑制效果。[1]
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	DMSO : 73 mg/mL (156.2 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) H2O : < 1 mg/mL (insoluble or slightly soluble)
关键字	Histone deacetylases \| deacetylase \| Quisinostat \| JNJ26481585 \| HDAC \| JNJ26854165(Quisinostat) \| Quisinostat dihydrochloride \| histone \| inhibit \| Inhibitor \| Quisinostat Dihydrochloride \| malignancies \| Apoptosis \| hematologic \| Autophagy \| JNJ-26481585 \| Quisinostat (JNJ-26481585) \| JNJ 26481585
相关产品	Guanidine hydrochloride \| Naringin \| Taurine \| Gefitinib \| Hydroxychloroquine \| 5-Fluorouracil \| Curcumin \| Stavudine \| Tributyrin \| L-Ascorbic acid \| Paeonol \| Sodium 4-phenylbutyrate
相关库	抑制剂库 \| 抗癌活性化合物库 \| 经典已知活性库 \| 已知活性化合物库 \| 抗衰老化合物库 \| DNA 损伤和修复分子库 \| 药物功能重定位化合物库 \| NF-κB 通路分子库 \| 抗癌临床化合物库 \| 抗癌药物库

Quisinostat 2HCl|||Quisinostat (JNJ-26481585) 2HCl|||JNJ26854165(Quisinostat) 2HCl|||JNJ-26481585 2HCl|TargetMol

TargetMol Chemicals Inc. 总部位于马萨诸塞州波士顿，致力于为全球生化领域科学家的研究提供专业的产品和服务。TargetMol?品牌的客户群分布于40多个国家和地区，已发展成为全球知名的化合物库和小分子化合物研究供应商。 TargetMol?可提供160多种满足不同需求的化合物库，以及多种类型的生化试剂产品，包括12000多种抑制剂、16000多种天然产物和各类多肽、抗体、生命科学试剂盒等，此外，我们还建设有CADD（计算机辅助药物设计）研究中心、药理实验室、药化合成平台三大技术中心，全方位满足客户的定制需求。凭借我们优质的产品和服务、快速高效的全球供应链和专业的技术支持，我们将有效帮助您缩短研发周期，取得更成功的结果。

成立日期	(12年)
注册资本	566.265100万人民币
员工人数	100-500人
年营业额	￥ 1亿以上
经营模式	贸易,工厂,试剂,定制,服务
主营行业	天然产物,生化试剂,分子生物学,分子砌块,生物技术服务